Guilherme Marques, president of Siemens Healthineers LatAm, discusses the health tech giant's regional strategy, covering how the firm rides out the region's economic and political storms, its participation in disease screening campaigns, digitalisation uptake, oncology integration, and much more.
Despite the uncertainty of [LatAm] markets - due to inflation, political issues or even social ones - these challenges are what make us stronger and perform better
Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts,…
Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
Indian pharma companies have been building a broader presence in LatAm markets over the past two decades. With well-established trade relations already in place, the region offers a series of unique…
A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s…
See our Cookie Privacy Policy Here